Logo

Cellular Genomics Raises $34.9M in Series C Financing

Jun 14, 2004

NEW YORK, June 14 (GenomeWeb News) - Cellular Genomics has raised $34.9 million in a Series C private equity financing round, the Branford, Conn.-based company said today.

 

Cellular Genomics plans to use the funding to advance its drug development programs into the clinic. The company applies its chemical genetics platform both for in-house drug discovery and in collaborations with pharmaceutical and biotechnology companies, including Affymetrix, Eli Lilly, and Pfizer.

 

Previous investors Coastview Capital and Connecticut Innovations were joined by new investors CDP Capital, RiverVest Venture Partners, and Toucan Capital in this round.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.